Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells

Abstract

Cancer cell-derived EVs can be used as effective carriers of Paclitaxel to their parental cells, bringing the drug into the cells through an endocytic pathway and increasing its cytotoxicity. However, due to the increased cell viability, the use of cancer cell-derived EVs must be further investigated before any clinical applications can be designed.

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

“…PEG is often used for its stealth functions in nanoparticle formulations because it is a hydrophilic (Bolwell et al, 1988;Crom et al, 1994;Wall and Wani, 1995;Clarke and Rivory, 1999;Lobert et al, 2000;Screnci et al, 2000;Hirschfeld et al, 2003;Forrest et al, 2006;Pommier, 2006;Yang et al, 2006;Kelland, 2007;Kreder and Dmochowski, 2007;Cai et al, 2010;Surapaneni et al, 2012;Wilson and Lippard, 2012;Yadav and Khan, 2013;Ferrati et al, 2015;Nirmalanandhan et al, 2015;Saari et al, 2015). and flexible polymer (Bergström et al, 1994).…”

Structural Analysis of Exosomes Using Different Types of Electron Microscopy

“…Currently, the cup shape of exosomes identified through negative staining has been considered to be their typical structure (Gyorgy et al, 2011;Thery et al, 2009). However, scanning EM (SEM) (Enderle et al, 2015), atomic force microscopy (Sharma et al, 2010), and cryo-transmission EM (TEM) (Montaner-Tarbes et al, 2016;Saari et al, 2015) revealed that exosomes have a round shape. In this study, we investigated the structure of exosomes using various EM approaches, including block preparation, sectioning, focused ion beam (FIB)-SEM, electron tomography, and cryo-TEM.…”

En el Infarto agudo al miocardio los niveles plasmáticos de microvesículas extracelulares se elevan más precozmente que el aumento de la Troponina-I

“…Actualmente, la caracterización de marcadores exosomales, sobre la fracción enriquecida de MVECs desde plasma, incluye expresión de tetraspaninas CD9/CD63 9, 22, 19 y estudios de tamaño mediante Nanoparticle Tracking Assay (NTA, Nanosight). 8,15,23,24 Nuestros datos permiten establecer que el enriquecimiento de MVEC desde plasma humano por un método comercial permite su caracterización mediante clásicos marcadores CD9 y CD63 9,19,22 . En una publicación reciente se describe una aproximación similar a la nuestra, pero en pacientes derivados a cirugía cardiovascular.…”